S&P 500 Climbs to New Record and EBay to Handle $110 Billion of Marketplace Volume in 2015

 S&P 500 Climbs to New Record and EBay to Handle $110 Billion of Marketplace
                                Volume in 2015

PR Newswire

NEW YORK, April 1, 2013

NEW YORK, April 1, 2013 /PRNewswire/ --

The Standard & Poor's 500 hit a new record Thursday morning; three weeks after
the Dow Jones beat its 2007 record. EBay executives said the Company aims to
handle $110 billion of sales volume in its marketplace in 2015 by expanding
globally.

Whether bull or bear The Stock Freak has got you covered! Sign up to receive
our free newsletters and stay up to date with stocks on the
run.http://www.TheStockFreak.com

Dollar General Corporation (NYSE: DG) - Dollar General Corp. had one of the
biggest volume advances on the NYSE on Thursday, trading nearly 31 million
shares. The Company announced Wednesday the pricing of an underwritten
secondary public offering of 30 million common shares at a price to the public
of $50.75 per share. 

Many mid or large cap stocks once started off asPenny stocks!

BlackBerry (Nasdaq: BBRY) - BlackBerry traded over 105 million shares on
Thursday after reporting mixed results that included a surprise profit in Q4.

Southcross Energy Partners, L.P. (NYSE: SXE) - Shares of SXE sank to a new
52-week low of $20.15 on Thursday after reporting fourth quarter and full year
2012 financial and operating results in the early morning.

Penny stockscan deliver sky-rocketing returns and are a popular choice among
many investors in the market because of how much lower they trade than big cap
companies.

Repros Therapeutics Inc. (Nasdaq: RPRX) - Repros Therapeutics was one of the
biggest advancers on the Nasdaq composite on Thursday seeing gains as high as
79% in intra-day trading. The Company's experimental drug to treat low levels
of testosterone met the main goals of a key study.

Gilead Sciences Inc. (Nasdaq: GILD) - GILD hit a new all-time high of $49.48
on Thursday after an ISI Group analyst said sales estimates must go "way way
up" on its experimental hepatitis C therapy.

To find similar research reports that are available for free follow the link
below and sign up at http://www.TheStockFreak.com  

Disclosure: TheStockFreak.com is not a registered investment advisor and
nothing contained in any materials should be construed as a recommendation to
buy or sell securities. Investors should always conduct their own due
diligence with any potential investment. Please read our report and visit our
website, for complete risks and disclosures.

SOURCE www.thestockfreak.com

Contact: Contact: For Media Only : Info@thestockfreak.com, Frank White,
Marketing Manager, +1-561-372-8372
 
Press spacebar to pause and continue. Press esc to stop.